Agenda

Saturday October 05, 2024

• 8:00 AM – 8:05 AM

  Welcome

  • Co-Chair
    • Corey LangerMD, FACP
    • Edward GaronMD, MS
• 8:05 AM – 8:20 AM

  Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - Surgical Approach

  • Presenter
    • Kemp KernstineMD, PhD
• 8:20 AM – 8:35 AM

  Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - Non-Surgical Approach

  • Presenter
    • Puneeth IyengarMD, PhD
• 8:35 AM – 8:45 AM

  Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - DISCUSSION

  • Panelist
    • Kemp KernstineMD, PhD
    • Puneeth IyengarMD, PhD
• 8:45 AM – 9:00 AM

  Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - YES

  • Presenter
    • Jason PorterMD
• 9:00 AM – 9:15 AM

  Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - NO

  • Presenter
    • Natalie VokesMD
• 9:15 AM – 9:25 AM

  Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - DISCUSSION

  • Panelist
    • Jason PorterMD
    • Natalie VokesMD
• 9:25 AM – 9:35 AM

  Break

• 9:35 AM – 10:35 AM

  Non-CME Innovation Theater - Sponsored by Catalyst

• 10:35 AM – 11:15 AM

  Recognizing and Managing Lambert-Eaton Myasthenic Syndrome Associated with Small Cell Lung Cancer

  • Presenter
    • Jennifer CarlisleMD
• 11:15 AM – 11:30 AM

  Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - Primetime

  • Presenter
    • Jyoti MalhotraMD, MPH
• 11:30 AM – 11:45 AM

  Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - Need More Time

  • Presenter
    • Salma JabbourMD
• 11:45 AM – 11:55 AM

  Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - DISCUSSION

  • Panelist
    • Jyoti MalhotraMD, MPH
    • Salma JabbourMD
• 11:55 AM – 12:05 PM

  Break

• 12:05 PM – 1:05 PM

  Non-CME Innovation Theater - Sponsored by DSI

• 1:05 PM – 1:35 PM

  Exhibit Hall

• 1:35 PM – 2:15 PM

  Targeting HER2-Mutant NSCLC: A Focus on Biomarker Testing and Targeted Therapies

  • Presenter
    • Lyudmila BazhenovaMD
• 2:15 PM – 2:30 PM

  Debate: KRAS Inhibitors Are Standard Second-Line - YES

  • Presenter
    • Kathryn ArbourMD
• 2:30 PM – 2:45 PM

  Debate: KRAS Inhibitors Are Standard Second-Line - NO

  • Presenter
    • Shirish Gadgeel
• 2:45 PM – 2:55 PM

  Debate: KRAS Inhibitors Are Standard Second-Line - DISCUSSION

  • Panelist
    • Kathryn ArbourMD
    • Shirish Gadgeel
• 2:55 PM – 3:10 PM

  Break

• 3:10 PM – 3:25 PM

  Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - The New Emperor

  • Presenter
    • Arjan GowerMD, MS
• 3:25 PM – 3:40 PM

  Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - The Emperor’s New Clothes

  • Presenter
    • Corey LangerMD, FACP
• 3:40 PM – 3:50 PM

  Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - DISCUSSION

  • Panelist
    • Arjan GowerMD, MS
    • Corey LangerMD, FACP
• 3:50 PM – 4:05 PM

  Debate: Mesothelioma: Is There a Role for Surgery? - PROs

  • Presenter
    • Neel ChudgarMD
• 4:05 PM – 4:20 PM

  Debate: Mesothelioma: Is There a Role for Surgery? - CONs

  • Presenter
    • Hedy Kindler
• 4:20 PM – 4:30 PM

  Debate: Mesothelioma: Is There a Role for Surgery? - DISCUSSION

  • Panelist
    • Hedy Kindler
    • Neel ChudgarMD

Sunday October 06, 2024

• 8:30 AM – 8:35 AM

  Welcome

  • Co-Chair
    • Corey LangerMD, FACP
    • Edward GaronMD, MS
• 8:35 AM – 8:50 AM

  Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - YES

  • Presenter
    • Jay LeeMD
• 8:50 AM – 9:05 AM

  Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - NO

  • Presenter
    • David GerberMD
• 9:05 AM – 9:15 AM

  Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - DISCUSSION

  • Panelist
    • David GerberMD
    • Jay LeeMD
• 9:15 AM – 9:30 AM

  Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - TKIs

  • Presenter
    • Mary FidlerMD
• 9:30 AM – 9:45 AM

  Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - Immunotherapy

  • Presenter
    • Lyudmila BazhenovaMD
• 9:45 AM – 9:55 AM

  Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - DISCUSSION

  • Panelist
    • Lyudmila BazhenovaMD
    • Mary FidlerMD
• 9:55 AM – 10:25 AM

  Exhibit Hall

• 10:25 AM – 11:05 AM

  EGFR Gene Mutations in Non-Small Cell Lung Cancer: Updates on Targeted Strategies

  • Presenter
    • Sawsan Rashdan
• 11:05 AM – 11:20 AM

  Debate: Should Liquid Biopsies Be Part of Initial Workup? - YES

  • Presenter
    • Hatim Husain
• 11:20 AM – 11:35 AM

  Debate: Should Liquid Biopsies Be Part of Initial Workup? - NO

  • Presenter
    • Kurt SchalperMD, PhD
• 11:35 AM – 11:45 AM

  Debate: Should Liquid Biopsies Be Part of Initial Workup? - DISCUSSION

  • Panelist
    • Hatim Husain
    • Kurt SchalperMD, PhD
• 11:45 AM – 12:30 PM

  Lunch

• 12:30 PM – 1:10 PM

  Large Cell Neuroendocrine Carcinoma of the Lung: Addressing Diagnostic Challenges and Understanding Current and Emerging Therapies

  • Presenter
    • Aman ChauhanMD
• 1:10 PM – 1:25 PM

  Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - PROS

  • Presenter
    • Puneeth IyengarMD, PhD
• 1:25 PM – 1:40 PM

  Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - CONS

  • Presenter
    • Drew Moghanaki
• 1:40 PM – 1:50 PM

  Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - DISCUSSION

  • Panelist
    • Drew Moghanaki
    • Puneeth IyengarMD, PhD
• 1:50 PM – 2:05 PM

  Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - PROS

  • Presenter
    • Edward GaronMD, MS
• 2:05 PM – 2:20 PM

  Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - CONS

  • Presenter
    • Helen RossMD
• 2:20 PM – 2:30 PM

  Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - DISCUSSION

  • Panelist
    • Edward GaronMD, MS
    • Helen RossMD